NASDAQ:LMAT - LeMaitre Vascular Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$35.04 -0.40 (-1.13 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$35.44
Today's Range$34.92 - $35.57
52-Week Range$26.37 - $41.28
Volume120,400 shs
Average Volume150,638 shs
Market Capitalization$695.25 million
P/E Ratio40.74
Dividend Yield0.78%
Beta0.57
LeMaitre Vascular logoLeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Receive LMAT News and Ratings via Email

Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LMAT
CUSIPN/A
Phone781-221-2266

Debt

Debt-to-Equity RatioN/A
Current Ratio6.65
Quick Ratio4.92

Price-To-Earnings

Trailing P/E Ratio40.74
Forward P/E Ratio32.15
P/E Growth2.21

Sales & Book Value

Annual Sales$100.87 million
Price / Sales6.71
Cash Flow$1.0725 per share
Price / Cash32.67
Book Value$5.70 per share
Price / Book6.15

Profitability

EPS (Most Recent Fiscal Year)$0.86
Net Income$17.17 million
Net Margins17.34%
Return on Equity16.66%
Return on Assets14.57%

Miscellaneous

Employees423
Outstanding Shares19,310,000

LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Monday, April 23rd. Investors of record on Tuesday, May 22nd will be paid a dividend of $0.07 per share on Thursday, June 7th. This represents a $0.28 annualized dividend and a yield of 0.80%. The ex-dividend date is Monday, May 21st. View LeMaitre Vascular's Dividend History.

How will LeMaitre Vascular's stock buyback program work?

LeMaitre Vascular declared that its Board of Directors has authorized a share buyback plan on Friday, July 28th 2017, which permits the company to buyback $7,500,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 1.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular Inc (NASDAQ:LMAT) announced its quarterly earnings data on Wednesday, April, 25th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.02. The medical instruments supplier had revenue of $25.99 million for the quarter, compared to analysts' expectations of $26.42 million. LeMaitre Vascular had a net margin of 17.34% and a return on equity of 16.66%. LeMaitre Vascular's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.16 EPS. View LeMaitre Vascular's Earnings History.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $1.05-1.13 for the period, compared to the Thomson Reuters consensus estimate of $0.98. The company issued revenue guidance of $106-109 million, compared to the consensus revenue estimate of $111.05 million.LeMaitre Vascular also updated its Q2 guidance to $0.41-0.43 EPS.

What price target have analysts set for LMAT?

5 analysts have issued 1 year target prices for LeMaitre Vascular's shares. Their predictions range from $33.00 to $40.00. On average, they anticipate LeMaitre Vascular's stock price to reach $35.80 in the next year. View Analyst Ratings for LeMaitre Vascular.

Who are some of LeMaitre Vascular's key competitors?

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the folowing people:
  • Mr. George W. LeMaitre, Chairman & CEO (Age 53)
  • Mr. David B. Roberts, Pres and Director (Age 54)
  • Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 53)
  • Dr. George D. LeMaitre M.D., FACS, Founder and Chairman of Scientific Advisory Board (Age 84)
  • Mr. Trent G. Kamke, Sr. VP of Operations (Age 47)

Has LeMaitre Vascular been receiving favorable news coverage?

Media coverage about LMAT stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. LeMaitre Vascular earned a news impact score of 0.04 on Accern's scale. They also assigned media coverage about the medical instruments supplier an impact score of 45.51 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.08%), Dimensional Fund Advisors LP (5.20%), Epoch Investment Partners Inc. (3.99%), Thomson Horstmann & Bryant Inc. (1.78%), Allianz Asset Management GmbH (1.70%) and Allianz Asset Management GmbH (1.70%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.

Which institutional investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Biondo Investment Advisors LLC, Fiera Capital Corp and Thomson Horstmann & Bryant Inc.. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Lawrence J Jasinski, Peter R Gebauer and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.

Which institutional investors are buying LeMaitre Vascular stock?

LMAT stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Sensato Investors LLC, King Luther Capital Management Corp, BlackRock Inc., WINTON GROUP Ltd, Epoch Investment Partners Inc., Campbell & CO Investment Adviser LLC and Dupont Capital Management Corp. View Insider Buying and Selling for LeMaitre Vascular.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $35.04.

How big of a company is LeMaitre Vascular?

LeMaitre Vascular has a market capitalization of $695.25 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.


MarketBeat Community Rating for LeMaitre Vascular (LMAT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.